Surviving lung cancer is just the beginning
More than 14,000 cases of lung cancer were diagnosed in Australia in 2022. Survival rates are the worst of all cancers, with just 22% surviving five years after diagnosis.
Jul 31, 2023
0
1
More than 14,000 cases of lung cancer were diagnosed in Australia in 2022. Survival rates are the worst of all cancers, with just 22% surviving five years after diagnosis.
Jul 31, 2023
0
1
Maintenance therapy with selinexor provides durable survival benefits for endometrial cancer with TP53 mutations, according to a study presented during the July 2023 session of the American Society for Clinical Oncology Plenary ...
Jul 28, 2023
0
1
Increased skin cancer screening in individuals with skin of color is not sufficient to address racial disparities in melanoma survival rates, according to a new JAMA Dermatology study by UPMC and University of Pittsburgh ...
Jul 26, 2023
0
1
Leiomyosarcoma is a type of soft tissue sarcoma that is hard to treat and associated with a poor prognosis. Scientists at the Institute of Cancer Research are working to better understand the biology of this cancer to develop ...
Jul 25, 2023
0
1
Gallbladder cancer is most common in people who have gallstones or have had gallstones in the past. While uncommon, most gallbladder cancers are discovered at a late stage when the prognosis is often poor and liver resection ...
Jul 24, 2023
0
0
A new study published in Gastroenterology aims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett's esophagus (BE).
Jul 20, 2023
0
7
Once cancer spreads to different parts of the body (known as metastasis), it is more challenging to treat. This is true in colorectal cancer that has spread to the liver. However, some patients with limited metastasis can ...
Jul 20, 2023
0
82
Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist ...
Jul 17, 2023
0
46
A new research paper was published in Oncotarget, titled, "Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series."
Jul 14, 2023
0
8
While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in ...
Jul 13, 2023
0
16